Denaverine: Difference between revisions
Kiran Singh (talk | contribs) Created page with "{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 451555899 | IUPAC_name = 2-(Dimethylamino)ethyl (2-ethylbutoxy)diphenylacetate | image =Denave..." |
m Protected "Denaverine": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)) |
(No difference)
|
Latest revision as of 19:41, 18 August 2015
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Pregnancy category |
|
Routes of administration | intramuscular injection, suppositories |
ATCvet code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 8% (suppositories), 37% (oral solution) |
Metabolism | mainly hepatic, at least 11 metabolites |
Elimination half-life | 34 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C24H33NO3 |
Molar mass | 383.52 g/mol |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
WikiDoc Resources for Denaverine |
Articles |
---|
Most recent articles on Denaverine |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Denaverine at Clinical Trials.gov Clinical Trials on Denaverine at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Denaverine
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Denaverine Discussion groups on Denaverine Patient Handouts on Denaverine Directions to Hospitals Treating Denaverine Risk calculators and risk factors for Denaverine
|
Healthcare Provider Resources |
Causes & Risk Factors for Denaverine |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Denaverine is an antispasmodic drug. It was developed in Germany and patented in 1974. Denaverine hydrochloride is used in veterinary medicine under the trade name Sensiblex as a muscle relaxant for the myometrium of cows and dogs during childbirth.[1] Under the trade name Spasmalgan, it has also been used in humans for the treatment of urogenital and gastrointestinal spasms.[2]
Mechanism of action
Denaverine, like papaverine, acts as a phosphodiesterase inhibitor. Additionally, it has anticholinergic effects.[3]
References
- ↑ Committee for Veterinary Medicinal Products: Denavering Hydrochloride Summary Report
- ↑ Dootz, H; Kuhlmann, A; Hoffmann, K (eds.). Rote Liste (in German) (2005 ed.). Aulendorf: Editio Cantor. 77 023. ISBN 3-87193-306-6.
- ↑ Dinnendahl, V, Fricke, U, ed. (2010). Arzneistoff-Profile (in German). 4 (23 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag. ISBN 978-3-7741-9846-3.
- Pages with script errors
- CS1 maint: Unrecognized language
- CS1 maint: Multiple names: editors list
- Template:drugs.com link with non-standard subpage
- Drugs with non-standard legal status
- Articles with changed ChemSpider identifier
- Articles with changed EBI identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles with changed InChI identifier
- Chemical articles with unknown parameter in Infobox drug
- Chemical pages without DrugBank identifier
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Antispasmodics
- Ethylamines
- Carboxylate esters
- Ethers
- Drug